JP2009541292A - 結晶塩酸デュロキセチン - Google Patents

結晶塩酸デュロキセチン Download PDF

Info

Publication number
JP2009541292A
JP2009541292A JP2009515962A JP2009515962A JP2009541292A JP 2009541292 A JP2009541292 A JP 2009541292A JP 2009515962 A JP2009515962 A JP 2009515962A JP 2009515962 A JP2009515962 A JP 2009515962A JP 2009541292 A JP2009541292 A JP 2009541292A
Authority
JP
Japan
Prior art keywords
organic solvent
duloxetine hydrochloride
solution
duloxetine
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009515962A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009541292A5 (enExample
Inventor
ピン ジャン，ウェイ
ロン ジャ，チュン
Original Assignee
アロー インターナショナル リミテッド
チョンチン シェンファーシー ファーマシューティカル カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36803801&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2009541292(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by アロー インターナショナル リミテッド, チョンチン シェンファーシー ファーマシューティカル カンパニー リミテッド filed Critical アロー インターナショナル リミテッド
Publication of JP2009541292A publication Critical patent/JP2009541292A/ja
Publication of JP2009541292A5 publication Critical patent/JP2009541292A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
JP2009515962A 2006-06-23 2007-06-21 結晶塩酸デュロキセチン Pending JP2009541292A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0612506.6A GB0612506D0 (en) 2006-06-23 2006-06-23 Crystalline duloxetine hydrochloride
PCT/GB2007/002325 WO2007148103A1 (en) 2006-06-23 2007-06-21 Crystalline duloxetine hydrochloride

Publications (2)

Publication Number Publication Date
JP2009541292A true JP2009541292A (ja) 2009-11-26
JP2009541292A5 JP2009541292A5 (enExample) 2010-05-13

Family

ID=36803801

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009515962A Pending JP2009541292A (ja) 2006-06-23 2007-06-21 結晶塩酸デュロキセチン

Country Status (10)

Country Link
US (2) US7799935B2 (enExample)
EP (1) EP2035404A1 (enExample)
JP (1) JP2009541292A (enExample)
CN (1) CN101627026A (enExample)
AU (1) AU2007262801B2 (enExample)
BR (1) BRPI0711954A2 (enExample)
CA (1) CA2656035A1 (enExample)
GB (1) GB0612506D0 (enExample)
NZ (1) NZ573212A (enExample)
WO (1) WO2007148103A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016222628A (ja) * 2015-06-03 2016-12-28 株式会社トクヤマ デュロキセチン塩酸塩の製造方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0612506D0 (en) 2006-06-23 2006-08-02 Arrow Int Ltd Crystalline duloxetine hydrochloride
EP2107057A1 (en) * 2008-04-04 2009-10-07 Ranbaxy Laboratories Limited Process for the preparation of pure duloxetine hydrochloride
US20120095239A1 (en) 2009-03-13 2012-04-19 Alembic Pharmaceuticals Limited A process for the preparation of duloxetine hydrochloride
CN103626735A (zh) * 2012-08-28 2014-03-12 石药集团中奇制药技术（石家庄）有限公司 一种盐酸度洛西汀晶型及其制备方法
CN106265528A (zh) * 2015-05-12 2017-01-04 法德生技药品股份有限公司 制备药物凝集体的方法
CN113603673B (zh) * 2020-11-16 2024-08-06 上海中西三维药业有限公司 一种盐酸度洛西汀的晶型、其制备方法及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005108386A1 (en) * 2004-05-11 2005-11-17 Cipla Limited Crystalline forms of duloxetine free base
JP2007523213A (ja) * 2004-12-23 2007-08-16 テバ ファーマシューティカル インダストリーズ リミティド 医薬的に許容できるデュロキセチンの塩及びその中間体の調製方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956388A (en) * 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
US5362886A (en) * 1993-10-12 1994-11-08 Eli Lilly And Company Asymmetric synthesis
WO2005019199A1 (en) 2003-08-25 2005-03-03 Hetero Drugs Limited Amorphous duloxetine hydrochloride
US20050197503A1 (en) * 2004-03-05 2005-09-08 Boehringer Ingelheim International Gmbh Process for the preparation of N-alkyl-N-methyl-3-hydroxy-3-(2-thienyl)-propylamines
EP1812428A2 (en) 2004-11-19 2007-08-01 Teva Pharmaceutical Industries Ltd Zolmitriptan crystal forms
WO2006058121A1 (en) 2004-11-23 2006-06-01 Bristol-Myers Squibb Company Crystalline forms of 3'-tert-butyl-3'-n-tert-butyloxycarbonyl-4-deacetyl-3'-dephenyl-3'-n-debenzoyl-4-o-methoxycarbonyl-paclitaxel
EP1776049A2 (en) * 2005-01-27 2007-04-25 Teva Pharmaceutical Industries Ltd. Duloxetine hcl polymorphs
EP1820800A1 (en) * 2006-02-17 2007-08-22 KRKA, tovarna zdravil, d.d., Novo mesto Crystalline forms of duloxetine hydrochloride and processes for their preparation
GB0612506D0 (en) 2006-06-23 2006-08-02 Arrow Int Ltd Crystalline duloxetine hydrochloride

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005108386A1 (en) * 2004-05-11 2005-11-17 Cipla Limited Crystalline forms of duloxetine free base
JP2007523213A (ja) * 2004-12-23 2007-08-16 テバ ファーマシューティカル インダストリーズ リミティド 医薬的に許容できるデュロキセチンの塩及びその中間体の調製方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN5009008258; ＳＹＮＴＨＯＮ　ＢＶ: ＲＥＳＥＡＲＣＨ　ＤＩＳＣＬＯＳＵＲＥ Ｖ．ＤＮ４９８０１１, 200510, Ｐ１１２９-１１３２, ＭＡＳＯＮ　ＰＵＢＬＩＣＡＴＩＯＮＳ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016222628A (ja) * 2015-06-03 2016-12-28 株式会社トクヤマ デュロキセチン塩酸塩の製造方法

Also Published As

Publication number Publication date
US20080021089A1 (en) 2008-01-24
GB0612506D0 (en) 2006-08-02
BRPI0711954A2 (pt) 2011-12-20
CN101627026A (zh) 2010-01-13
CA2656035A1 (en) 2007-12-27
US20100331388A1 (en) 2010-12-30
AU2007262801A1 (en) 2007-12-27
US7799935B2 (en) 2010-09-21
EP2035404A1 (en) 2009-03-18
US8093407B2 (en) 2012-01-10
NZ573212A (en) 2012-01-12
AU2007262801B2 (en) 2013-01-31
WO2007148103A1 (en) 2007-12-27

Similar Documents

Publication Publication Date Title
JP5247687B2 (ja) 結晶塩酸デュロキセチン
JP2009541292A (ja) 結晶塩酸デュロキセチン
CN101440079B (zh) 制备外消旋西酞普兰和/或s-或r-西酞普兰的方法
UA66359C2 (uk) Спосіб одержання рацемічних або оптично активних сполук
JP2009541291A (ja) 結晶塩酸デュロキセチン
JP2011503122A (ja) ４，５−ジメトキシ−１−（メチルアミノメチル）−ベンゾシクロブタンの分離
JP2009541291A5 (enExample)
JP2009541292A5 (enExample)
WO2014009964A1 (en) Process for enantiomeric enrichment of 2 ', 6 ' - pipecoloxylidide
EP2358369A1 (en) Process for the preparation of substantially optically pure repaglinide and precursors thereof
JP2025518760A (ja) ピコリンアミド殺真菌剤化合物の結晶形態
WO2009080469A1 (en) Process for the preparation of clopidogrel bisulphate form i
EP2040697A2 (en) Polymorphic form of duloxetine hydrochloride
JP2024516199A (ja) バルベナジンの合成方法
WO2009118758A2 (en) Novel crystalline forms of desvenlafaxine succinate
EP2177221A1 (en) Process for the preparation of substantially optically pure Repaglinide and precursors thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100326

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100326

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20110119

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20110216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121023

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130122

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130222

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20131029